Evidence map›Paper›PMID 26937653›Full record

ArticlePloS one2016

Interleukin-1β Promoter Polymorphism Enhances the Risk of Sleep Disturbance in Alzheimer's Disease.

You Yin, Yan Liu, Xiao Pan, Rui Chen, Peng Li, Hui-Juan Wu, Zheng-Qing Zhao, Yan-Peng Li, Liu-Qing Huang, Jian-Hua Zhuang and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Interleukin-1 Beta-A Friend or Foe in Malignancies?International journal of molecular sciences · 2018
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

You YinDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Yan LiuDepartment of Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiao PanDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Rui ChenDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Peng LiDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Hui-Juan WuDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Zheng-Qing ZhaoDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Yan-Peng LiDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Liu-Qing HuangDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Jian-Hua ZhuangDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Zhong-Xin ZhaoDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Second Military Medical University · CNXinHua Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sleep alleviates Alzheimer's disease (AD)-related neuropathological processes, whereas sleep disturbance in AD patients is associated with elevated peripheral inflammatory cytokine levels. In the present study, we assessed interleukin (IL)-1β and APOEε4 polymorphisms for association with susceptibility of sleep disturbances in AD patients. A total of 123 pretreated AD patients and 120 age-, gender- and education level-matched healthy controls were recruited for two consecutive full-night polysomnography and measurement of Epworth Sleepiness Scale (ESS) scores for sleep-wake disturbance. Their genomic DNA was analyzed for IL-1β and APOEε4 SNPs using ligase detection reaction (LDR) technology. Blood levels of IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α) were measured using ELISA after lipopolysaccharide (LPS) stimulation. The odds ratio and 95% confidence interval for genotype-specific risk were calculated using an unconditional logistic regression model and adjusted by age, gender, educational levels, body mass index (BMI), and activities of daily living (ADL). Compared to the non-APOEε4/ε4 genotype, APOEε4/ε4 significantly increased the risk of AD (APOEε4/ε4 vs. non-APOEε4/ε4, adjusted OR = 4.33, 95% CI = 1.33-14.10, p = 0.015). Compared to the IL-1β CC genotype (-31), the TT genotype significantly increased the risk of AD (TT vs. CC, adjusted OR = 1.72, 95% CI = 1.13-2.61, p = 0.010). AD patients carrying the APOEε4 allele and the IL-1β TT genotype showed less time in bed, longer sleep latency and REM latency, more awakenings, and a lower SWS percentage than those carrying CC/CT combined genotypes. In addition, blood IL-1β levels were significantly greater in AD patients carrying both the APOEε4 allele and the IL-1β-31TT genotype than in those carrying the APOEε4 allele and the -31 TC or CC genotype. In conclusion, this study provides the first evidence indicating that the IL-1β-31TT genotype and homozygous APOEε4 combined are associated with increased risk of developing AD with sleep disturbance.

Indexed as

AgedAlzheimer DiseaseApolipoprotein E4Case-Control StudiesCells, CulturedFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHumansInterleukin-1betaLeukocytes, MononuclearLipopolysaccharidesMalePolymorphism, Single NucleotidePromoter Regions, GeneticApolipoprotein E4IL1B protein, humanInterleukin-1betaLipopolysaccharides

Identifiers

PMID26937653
PMCPMC4777499
OpenAlexW2291734322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.